https://www.acc.org/education-and-meetings/meetings/meeting-items/2023/07/01/01/webinar-optimizing-ldl-c
Optimizing LDL-C: The Basics and Beyond - American College of Cardiology
ldl cthe basicsand beyondamerican collegeoptimizing
https://www.attackheartdisease.com/
What is Bad Cholesterol (LDL-C)? | Attack Heart Disease
Learn what LDL-C (bad cholesterol) is, the risks of having a high LDL number, factors to consider in reducing your LDL, and why you should test your LDL-C.
what isbad cholesterolldlattackheart
https://pmc.ncbi.nlm.nih.gov/articles/PMC8617782/
Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering - PMC
Cardiovascular diseases are the leading causes of the death around the world. An elevation of the low-density lipoprotein cholesterol (LDL-C) level is one of...
the roleldl cbioactivitydietarypolyphenols
https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2016/01/11/23/18/Discordance-Between-Apolipoprotein-B-and-LDL
Discordance Between ApoB and LDL-C Predicts Calcification - American College of Cardiology
ldl c
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2023.1114176/full
Frontiers | Role of LDL-C level alteration in increased mortality risks in spontaneous...
Background: Current studies indicate a contradictory relationship between decreased mortality risks of spontaneous intracerebral hemorrhage (sICH) and elevat...
ldl c
https://www.acc.org/latest-in-cardiology/journal-scans/2017/01/30/15/23/safety-of-very-low-low-density-lipoprotein-cholesterol
Safety of Very Low LDL-C Levels With Alirocumab - American College of Cardiology
Melvyn Rubenfire, MD, FACC
ldl c
https://www.healthday.com/healthpro-news/cardiovascular-diseases/apolipoprotein-b-cost-effective-for-guiding-primary-prevention-lipid-lowering-therapy
ApoB vs LDL-C: Cost-Effective Guide for Lipid-Lowering Therapy
Apolipoprotein B can be used as a cost-effective marker to guide primary prevention lipid-lowering therapy compared with low-density lipoprotein cholesterol...
ldl ccost effectivelipid loweringapobvs
https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2019/09/01/12/22/ORION-11
Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent - American...
Anthony A. Bavry, M.D., M.P.H., FACC